Cure.’s Post

AI can revolutionize medicine by enhancing drug development efficiency, accuracy and cost-effectiveness. Cure and The New York Academy of Sciences with Nicholas Dirks bring you a very special episode of Tuesday Talks with Seema Kumar with a panel of experts including George Church of Harvard Medical School, Maria Luisa Pineda, PhD. of Envisagenics, Grant W Mitchell, MD, MBA, of Every Cure and Thomas Fuchs of Icahn School of Medicine at Mount Sinai who will discuss AI's transformative role in bringing patients more effective treatments faster. #aiforgood #wewillcure

Stanford Chair of Genetics: "Modern medicine is broken beyond repair" With healthcare systems creaking under the weight of chronic under-investment and record-high waiting lists, Prof Michael Snyder is calling for a healthcare revolution that throws out generic care, prescriptions and treatment in favour of a truly personalised approach that capitalises on the latest genetic, tech and medical breakthroughs. But can his vision ever become a reality in the face of fervent resistance from Big Pharma and other powerful vested interests with bottomless pockets? Unfiltered https://lnkd.in/eFCagBu9

The medicine of the future could be artificial life forms https://lnkd.in/dTCFFSXm

Explore how crowdsourcing can revolutionize translational medicine and medical innovation. Learn about the invaluable role of citizen science in enhancing clinical research, particularly in rare disease studies, and how AI is amplifying these efforts. Discover why involving patients and caregivers can accelerate scientific discoveries and empower individuals in their health journey.

Two burning questions for the AI curious among us: 1) When was artificial intelligence first used in medicine? 2) What do we expect to be the first medicine to hit the market thanks to AI? Here are your answers, you can freely quote me when you're showing off your state-of-the-art knowledge on AI and medicine... 😉 1. It was back in 1973 when the "Stanford University Medical Experimental–Artificial Intelligence in Medicine", a time-shared computer system, was created, combining the know-how of many clinical and biomedical researchers from several institutions. 2. Insilico Medicine (Hong Kong, New York) — used AI to develop an experimental drug for the incurable lung disease idiopathic pulmonary fibrosis. The treatment is in mid-stage trials in the US and China with some results expected early 2025. Don't forget for all your business development and recruitment needs, we're right there for you: mecon@consultant.com

Let’s talk about speech, baby 💬 New publication alert! 👇 We summarised current evidence of digitally collected speech biomarkers in #motorneurondisease #amyotrophiclateralsclerosis Led by superstar medical student Molly Bowden, our team systematically reviewed 40 studies using digital devices to assess speech. Key takeaways: 1️⃣ Changes in speech show early potential in differentiating people with MND and healthy controls 2️⃣ Speech is a promising potential avenue for early detection of MND 3️⃣ Digital data collection enables assessments at home and can reduce the burden of travel Whilst further research is definitely needed, reviews like these provide essential backgrounds to what has (and hasn’t!) worked so far. Check out the full paper at NPJ Digital Medicine: link in comments 👋 ______________________________________________________ A great way to round off a busy year and looking forward to 2024... ...but for now I’m off for two weeks of hibernation with my pups!

Discover how these natural history studies provide essential data for creating personalised treatment plans – and what this means for the future of precision medicine. 📚 Our latest blog has all the details. 👇 https://lnkd.in/eVrUGyFE #ClinicalTrials #PrecisionMedicine

Exciting news! The latest trends in drug discovery and clinical translation are here, and it's all about human iPSC models. Watch our iForum™ Innovation Showcase 2024 webinar to learn how these revolutionary models are speeding up the drug discovery process. Access this On-Demand for data-driven examples and case studies across cardiac, hepatic, neural, and immune systems. Let's dive deep into this game-changing technology together! Watch here: https://ow.ly/1mpF50QCn97 #DrugDiscovery #iPSC #StemCells #DrugDevelopment #3dCellCulture

Looking forward to Desiree Abdurrachim's talk on Multi-modal AI Digital Pathology to Accelerate MASH Drug Discovery! Have you secured your seat for the 8th Digital Pathology & AI Congress Asia 2024 yet?

The accepted LOI submission is for an automated depression and anxiety severity measurement tool utilizing multiple behavioral and physiological indices of depression in a machine learning (ML) model to derive clinician-reported outcomes for depression and anxiety based on the Hamilton Depression Rating Scale (HAM-D) and Hamilton Anxiety Rating Scale (HAM-A) scores.